NCT03794154撤回4 期
A PHASE IV, SINGLE-DOSE, OPEN-LABEL, RANDOMIZED, 2-WAY CROSSOVER STUDY TO DETERMINE THE BIOEQUIVALENCE OF DULOXETINE HYDROCHLORIDE HARD GELATINOUS CAPSULE WITH DELAYED RELEASE MICROGRANULES (60 MG; PFIZER S.R.L - ARGENTINA.) COMPARED TO CYMBALTA (REGISTERED) MICROGRANULES (60 MG; ELI LILLY DO BRASIL LTDA) IN HEALTHY MALE RESEARCH SUBJECTS UNDER FED CONDITIONS
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 撤回
- 发起方
- Pfizer
- 主要终点
- Area under the plasma concentration-time curve
研究概览
简要总结
In Brazil, duloxetine is currently available as hard gelatinous capsule with delayed release microgranules for oral administration containing enteric-coated pellets of 33.7, or 67.3 mg of duloxetine hydrochloride equivalent to 30 mg or 60 mg of duloxetine (Cymbalta®), respectively.
The Sponsor has developed a hard gelatinous capsule with delayed release microgranules formulation containing enteric-coated pellets of 33.7, or 67.3 mg of duloxetine hydrochloride equivalent to 30, or 60 mg of duloxetine, respectively.
The purpose of this study is to verify through a single dose study, if the test formulation of duloxetine is bioequivalent to the reference formulation (Cymbalta®) when administered with the same dosage and under fed conditions in healthy male research subjects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Healthy male research subjects who, at the time of screening, are between the ages of 18 and 55 years, inclusive.
- •Body mass index (BMI) of 18.5 kg/m2 to 24.9 kg/m2, and a total body weight >50 kg (>110 lbs).
- •Evidence of a personally signed and dated informed consent document indicating that the research subject has been informed of all pertinent aspects of the study.
- •Research subjects that never smoked.
- •Research subjects who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, and other study procedures.
排除标准
- •Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease.
- •Clinically significant infections within the past 3 months, evidence of any infection within the past 7 days, history of disseminated herpes simplex infection or recurrent (>1 episode) or disseminated herpes zoster.
- •Vaccination with live or attenuated vaccines within 6 weeks prior to dosing.
- •A history of suicidal thoughts, behavior or suicide attempts.
- •History of narrow angle glaucoma.
- •Any condition possibly affecting drug absorption (eg, gastrectomy, colon resection, etc.).
- •History of or current positive results for any of the following serological tests: hepatitis B surface antigen (HBsAg), hepatitis B core antibody (HBcAb), anti hepatitis C core antibody (HCV Ab), or human immunodeficiency virus (HIV) 1 and
- •Malignancy or a history of malignancy.
- •A positive urine drug test.
- •A positive alcohol screen.
- •History of regular alcohol consumption exceeding 21 drinks/week for male research subjects [1 drink = 5 ounces (150 mL) of wine or 12 ounces (360 mL) of beer or 1.5 ounces (45 mL) of hard liquor] within 6 months before screening.
- •Use of tobacco or all nicotine containing products.
- •Treatment with an investigational drug within 6 months or 5 half lives preceding the first dose of investigational product (whichever is longer).
- •Fertile male subjects who are unwilling or unable to use a highly effective method of contraception as outlined in this protocol for the duration of the study and for at least 28 days after the last dose of investigational product.
- •Use of prescription or nonprescription drugs and dietary supplements within 14 days or 5 half lives (whichever is longer) prior to the first dose of investigational product.
- •Consumption of grapefruit or grapefruit related citrus fruits (eg, Seville oranges, pomelos) or juices within 7 days prior to dosing.
- •Blood donation (excluding plasma donations) of approximately 1 pint (500 mL) or more within 3 months prior to screening until collection of the final PK blood sample (Period 2, Day 4).
- •History of sensitivity to heparin or heparin induced thrombocytopenia.
- •History of hypersensitivity to duloxetine or any of the components in the formulation of the study products.
- •Unwilling or unable to comply with the criteria in the Lifestyle Requirements section of this protocol.
- •Use of any medicinal product that is an inductor or strong inhibitor of CYP450 1A2 or 2D6 (eg, rifampicin, omeprazole, fluvoxamine, ciprofloxacin, fluoxetine, paroxetine, etc) within two weeks before administration of the investigational product and at any time during the study.
- •Use of any medicinal product that inhibits monoamine oxidase A or B (eg, phenelzine, isocarboxacid, linezolid) within two weeks before administration of the investigational product and at any time during the study till at least 5 days after the last dose of investigational product.
研究组 & 干预措施
Duloxetine hydrochloride
Experimental
Duloxetine hydrochloride hard gelatinous capsule 60 mg by mouth on Day 1 of period 1 or 2
干预措施: Duloxetine hydrochloride capsule (Drug)
Cymbalta
Active Comparator
Duloxetine hydrochloride hard gelatinous capsule 60 mg as Cymbalta by mouth on Day 1 of period 1 or 2
干预措施: Cymbalta capsule (Drug)
结局指标
主要结局
Area under the plasma concentration-time curve
时间窗: Upto 72 hours post dose
Area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration (AUClast)
Maximum plasma concentration (Cmax)
时间窗: Upto 72 hours post dose
次要结局
- Area under the plasma concentration-time curve from time zero extrapolated to infinite time(Upto 72 hours post dose)
- Time to first occurrence of Cmax (Tmax)(Upto 72 hours post dose)
- Terminal phase rate constant (kel)(Upto 72 hours post dose)
研究者
相似试验
撤回
4 期
A Study of Duloxetine Hydrochloride Hard Gelatinous Capsule Compared To CymbaltaHealthyNCT03729284Pfizer
已完成
4 期
Relative Bioavailability Study of Zoloft Oral Solution to Zoloft TabletsHealthyNCT03711708Pfizer's Upjohn has merged with Mylan to form Viatris Inc.36
Unknown
3 期
Efficacy and Safety of Octreotide Capsules (MYCAPSSA) in AcromegalyAcromegalyNCT03252353Chiasma, Inc.56
已完成
4 期
A Phase IV, single dose JENVAC (Inactivated JE Vaccine) vs. Chinese SA-14-14-2 (Live JE Vaccine) vaccineCTRI/2014/02/004386Bharat Biotech International Ltd
进行中（未招募）
1 期
A Phase IIa, open-label, dose-titration, multicentre study to assess the safety and preliminary efficacy of NI-0401 in patients with acute cellular renal allograftt rejectioEUCTR2007-001857-24-GBovImmune S.A.12